Gencurix announces further evidences for GenesWell(TM) BCT
SEOUL, South Korea, Dec. 3, 2018 /PRNewswire-AsiaNet/ Gencurix, the developer of a molecular diagnostic test, GenesWell(TM) BCT, reported another evidence for the efficacy of the product. Photo - https://photos.prnasia.com/prnh/20181203/2315344-1 GenesWell(TM) BCT is a gene expression profili...
Read more https://view-release/?pr-id=76601